In nonhospitalized, unvaccinated adults with COVID-19, molnupiravir reduced hospitalization or death at 29 d

Henry S Sacks

doi:10.7326/J22-0017

In nonhospitalized, unvaccinated adults with COVID-19, molnupiravir reduced hospitalization or death at 29 d

Ann Intern Med. 2022 Apr;175(4):JC40. doi: 10.7326/J22-0017. Epub 2022 Apr 5.

Author

Henry S Sacks¹

Affiliation

¹ Icahn School of Medicine at Mount Sinai, New York, New York, USA (H.S.S.).

PMID: 35377719
DOI: 10.7326/J22-0017

Abstract

Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386:509-20. 34914868.

Publication types

Comment

MeSH terms

Adult
COVID-19*
Cytidine / analogs & derivatives
Hospitalization
Humans
Hydroxylamines / adverse effects
SARS-CoV-2

Substances

Hydroxylamines
Cytidine
molnupiravir